93.18
-0.58%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mirum Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Mirum Pharmaceuticals is based in Foster City, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MIRM. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $521.3m and a net loss of $23.4m. At that date it held total assets of $842.8m and shareholders' equity of $314.7m.
We are a biopharmaceutical company dedicated to transforming the treatment of rare diseases.
We have three approved medicines: LIVMARLI® (maralixibat) (“Livmarli”), CHOLBAM® (cholic acid) capsules (“Cholbam”), and CTEXLI® (chenodiol) tablets (“Ctexli”).
Livmarli is a novel, orally administered, minimally-absorbed ileal bile acid transporter (“IBAT”) inhibitor (“IBATi”) that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (“ALGS”) in the United States (“U.S.”), the European Union (“EU”) and various other countries around the world and for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (“PFIC”) in the U.S., Canada and Japan and for the treatment of PFIC in the EU. We market and commercialize Livmarli in the U.S., Canada and certain countries in Europe through our specialized and focused commercial team. We have also entered into license and distribution agreements with several rare disease companies for the commercialization of Livmarli in additional countries. We are also seeking to add to the approved indications for Livmarli by conducting the EXPAND study in settings of cholestatic pruritus due to other rare conditions.
Quoted from its 10-K, filed 25 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Jul 2019
- Employees
- 369
- Website
- mirumpharma.com ↗
- Head office
- 989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA, 94404
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Michael GreyIndependent Chairman of the Board, since 2018$408,513
- Mr. Peter RadovichPresident, Chief Operating Officer$3.3m
- Mr. Christopher PeetzChief Executive Officer, Co-Founder, Director, since 2018$6.6m
- Mr. Eric BjerkholtChief Financial Officer$2.0m
- Dr. Pamela VigChief Scientific Officer, Head of Research$1.5m
- Ms. Lara LongpreChief Development Officer$1.5m
- Dr. Joanne QuanChief Medical Officer$3.6m
- Mr. Doug SheehyChief Legal officer
- Ms. Laura BregeIndependent Director$383,513
- Dr. Lon CardonIndependent Director$353,513
- Mr. William FaireyIndependent Director$368,513
- Dr. Laurent FischerIndependent Director$378,513
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 17
- Environment
- 4
- Social
- 23
- Governance
- 23
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mirum Pharmaceuticals Inc has several strengths that contribute to its success in the pharmaceutical industry. These strengths include:
Weaknesses
- Despite its strengths, Mirum Pharmaceuticals Inc also faces certain weaknesses, which need to be addressed to maintain its competitive edge:
Opportunities
- Mirum Pharmaceuticals Inc can leverage various opportunities to drive growth and expansion in the market:
Threats
- Mirum Pharmaceuticals Inc faces several threats that could impede its growth and performance:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.